Gynecologic Oncology

Results of a new study found that less than half of patients with advanced cervical cancer are receiving all 3 of the therapies considered standard of care for the disease: external beam radiation therapy, brachytherapy, and chemotherapy.

Pembrolizumab (Keytruda) was well tolerated and demonstrated promising antitumor activity in patients with PD-L1–positive advanced cervical squamous cell cancer.

Regular screening for cervical cancer was found to be associated with an overall mortality prevention rate of 83%.

Patients with endometrial and cervical cancer reported significantly less acute gastrointestinal toxicity when treated with pelvic intensity-modulated radiation therapy as opposed to standard pelvic radiation therapy.

Combining the diabetes drug metformin with everolimus and letrozole resulted in a clinical benefit rate of 60% in women with advanced or recurrent endometrioid endometrial cancer.

Vaginal brachytherapy has been linked to improved survival in women with stage I endometrioid adenocarcinoma of the uterus.

Emily M. Ko, MD, discusses the implications of two clinical trial findings for patients with endometrial cancer, and how several risk factors may lead to a surgical treatment delay.

Emily Ko, MD, assistant professor of Obstetrics and Gynecology, University of Pennsylvania Health System, discusses why surgery is an effective option for patients with endometrial cancer.

As a group, Rio Grande Urology shares a sense of obligation and culture. Its leaders have embraced an integrative model approach and sees the advantages of it.

The FDA has approved the cobas HPV Test for use with SurePath Preservative Fluid for the detection of human papilloma virus (HPV) in cervical cells.

A new NCCN guideline for the management of vulvar cancer outlines the use of resection, radiation therapy, and chemotherapy based on disease site and stage, recognizing that only 2 randomized treatment trials have been completed.

Treatment with trabectedin significantly improved progression-free survival compared with dacarbazine in women with advanced uterine leiomyosarcoma, according to a subgroup analysis of the phase III SAR-3007 trial.

Today, in his laboratory at Columbia University, Murty Vundavalli, PhD continues working to understand the genetic and epigenetic aspects of cervical cancer in an attempt to elucidate prognostic markers of response to treatment.

With technological advancements in genome sequencing, researchers are now gaining a more detailed picture of the genetic drivers of cervical cancer and the important role that the human papillomavirus, responsible for the vast majority of cervical cancer cases, plays in molding the genetic profile of this disease.

Dr. Noah Kauff discusses how hysterectomy, in addition to standard risk-reducing salpingo-oophorectomy (RRSO) measures, should be considered in BRCA+women to reduce the risk of serous uterine cancers.

Adding fosaprepitant (Emend) to an antiemetic regimen significantly improved emesis control versus standard care in women receiving radiotherapy and cisplatin for cervical cancer.

Tom Herzog, MD, discusses the vaccine ADXS11-001 (axalimogene filolisbac) in patients with persistent or recurrent metastatic cervical cancer.

Noah D. Kauff, MD, FACOG, gynecologist and geneticist, director, Ovarian Cancer Screening and Prevention, Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses the main challenges in treating uterine cancer.

Palliative care should address the unique symptom profile of gynecologic cancer and be tailored to individual socioeconomic environments.

Nooshin Hashemi Sadraei, MD, assistant professor of medicine, Department of Internal Medicine, University of Cincinnati, discusses biomarkers in HPV-induced tumors, including cervical, anal, and oropharyngeal cancers.